基礎インスリン（持効型インスリン）の世界市場-2023-2030

市場概要

基礎インスリン（持効型インスリン）の世界市場は、2022年に2億3,480万米ドルに達し、2030年には最大3億3,160万米ドルに達することで有利な成長を示すと予測されます。世界の基礎インスリン（持効型インスリン）市場は、予測期間中（2023-2030年）に4.5%のCAGRを示すと予測されています。

糖尿病の罹患率の上昇、有望な返済ガイドライン、製品導入、製品認可、統合、投資、提携、拡大などの市場開拓が、世界の基礎インスリン（持効型インスリン）市場の成長を押し上げています。この市場の主要プレーヤーには、Novo Nordisk AS、Sanofi Aventis、Bioconなどが含まれます。

市場力学

糖尿病患者の増加が基礎インスリン（持効型インスリン）市場の成長を促進する

糖尿病患者の増加は、世界の基礎インスリン（持効型インスリン）市場の成長を牽引しています。例えば、Access to Medicine Foundationによると、糖尿病は世界的に急速に増加し、年間670万人の死亡を引き起こしています。インスリンへのアクセスは、ますます重要な多国籍の健康上の重要性を持っています。糖尿病患者数は、2030年には6億4,300万人、2045年には7億8,300万人に達すると予測されており、インスリンへのアクセスに著しい不平等がある低・中所得国（LMICs）で最も急速に増加すると考えられています。

さまざまな患者支援プログラムの存在が、市場成長の好機をもたらす

さまざまな患者支援プログラムの存在は、今後数年間、市場に有望な成長機会をもたらします。例えば、Lilly Cares Program、Novo Nordisk Patient Assistance Program（PAP）NovoCare、Insulins ValYOU Savings Program、Direct Purchase Program、Insulin Glargine Follow-On Biologicなどが、インスリン購入時に低価格または返済を提供しています。

厳しい規制当局が市場の成長を妨げる

インスリン製品の開発と商業化を管理する厳しい規制当局の存在は、世界の基礎インスリン（持効型インスリン）市場の成長を鈍化させます。例えば、インスリンの開発と商業化を管理する主な規制当局には、FDAとEMAがあります。上記のような要因が、基礎インスリン（持効型インスリン）市場の成長を制限しています。

COVID-19の影響分析

COVID-19のパンデミックや世界各国の封鎖により、あらゆる業種の企業の財務状況が影響を受けています。そのため、COVID-19の公衆衛生上の緊急事態の期間中、米国食品医薬品局（FDA）は、スポンサーと研究者を支援し、試験参加者の安全を確保し、適正臨床実施（GCP）を遵守し、試験の完全性に対するリスクを最小限に抑えるための一般的な配慮を含むガイドラインを発表しました。

ロシア・ウクライナ紛争影響分析

ロシア・ウクライナ紛争は、この地域における主要な市場プレイヤーの不在と低い普及率のため、世界の基礎インスリン（持効型インスリン）市場に中程度の影響を及ぼすと推定されます。しかし、ロシア軍の侵攻に耐えながら、ウクライナの診療所は死者数の増加や限られた医療備蓄に追われています。あらゆる種類の医薬品が不足しているが、インスリンの備蓄へのアクセスが制限されているため、コントロールされていない糖尿病に関連する障害が増加しています。また、原材料の輸出入の影響は、予測期間中、世界の基礎インスリン（持効型インスリン）市場の成長にほとんど影響を与えないと予想されます。

目次

第1章 調査手法とスコープ

• 調査手法
• 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 市場の開拓
    • 普及率の向上
  • 抑制要因
    • 副作用
  • 機会
    • 保険償還
  • 影響分析

第5章 産業分析

• ポーターの5フォース分析
• サプライチェーン分析
• 価格分析
• 法規制の分析

第6章 COVID-19の分析

第7章 製品タイプ別

• Lantus
• Levemir
• Toujeo
• Tresiba
• Basaglar
• インスリンGlargineバイオシミラー

第8章 用途別

• 1型糖尿病
• 2型糖尿病

第9章 流通チャネル別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • その他アジア太平洋地域
• 中東・アフリカ地域
  • 地域別の主なダイナミクス

第11章 競合情勢

• 競合シナリオ
• 市況ポジショニング/シェア分析
• M&A（合併・買収）分析

第12章 企業プロファイル

• Novo Nordisk AS
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展状況
• Sanofi Aventis
• Biocon
• Julphar
• Pfizer
• Ganli Pharmaceutical Co., Ltd
• Mylan
• Wockhardt
• Eli Lily

第13章 付録

Market Overview

The Global Basal Insulin (Long-Acting Insulin) Market reached US$ 234.8 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 331.6 million by 2030. The global basal insulin (long-acting insulin) market is expected to exhibit a CAGR of 4.5% during the forecast period (2023-2030).

The rising incidence of diabetes, promising repayment guidelines, and market developments like product introduction, product authorizations, consolidations, investments, partnerships, and expansion among others are boosting the global basal insulin (long-acting insulin) market growth. The key players in this market include Novo Nordisk AS, Sanofi Aventis, and Biocon among others.

Market Dynamics

An Increase In Diabetes Cases Drives The Growth Of The Basal Insulin (Long-Acting Insulin) Market.

The growing cases of diabetes are driving the global basal insulin (long-acting insulin) market growth. For instance, according to the Access to Medicine Foundation, diabetes increases rapidly globally, inducing 6.7 million deaths annually. Access to insulin is an increasingly critical multinational health importance. The number of individuals with diabetes globally is anticipated to surpass 643 million by 2030, and 783 million by 2045 rising most quickly in low- and middle-income countries (LMICs), where there is stark inequity in access to insulin.

Presence Of Various Patient Assistance Programs Creates Lucrative Opportunities For Market Growth.

The presence of various patient assistance programs presents the market with prospective growth opportunities in the upcoming years. For instance, Lilly Cares Program, Novo Nordisk Patient Assistance Program (PAP) NovoCare, Insulins ValYOU Savings Program, Direct Purchase Program, and Insulin Glargine Follow-On Biologic among others provide low-cost or repayment on insulin purchases.

Stringent Regulatory Authorities Hamper the Growth of the Market.

The presence of stringent regulatory authorities controlling the development and commercialization of insulin products slows the global basal insulin (long-acting insulin) market growth. For instance, the major regulatory authorities controlling the development and commercialization of insulin include the FDA and EMA. Above mentioned factors are limiting the basal insulin (long-acting insulin) market growth.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations throughout the world. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the global basal insulin (long-acting insulin) market, owing to the low prevalence and absence of key market players in this region. However, persisting to countenance invasions from Russian armies, Ukrainian clinics are pushed by rising numbers of deaths and limited medical reserves. There are deficiencies across all kinds of medicine, but restricted access to insulin reserves has guided to an uptick in disorders associated with uncontrolled diabetes. Also, the influence of the import and export of raw materials are anticipated to have little influence over the global basal insulin (long-acting insulin) market growth over the forecast period.

Segment Analysis

The global basal insulin (long-acting insulin) market is segmented based on product type, application, distribution channels and region.

Hospital Pharmacies Segment Accounts for 40% of the Market Share.

Owing to the increasing number of hospitals, the availability of investigational developments, and ease of reimbursement, the hospital pharmacies segment is estimated to hold 42.3% of the global market share. For instance, according to the Republic of Estonia Agency of Medicines, in 2022, the total earning of hospital pharmacies was 137 million euros, with an upsurge of 3% in total compared to previous results.

Geographical Analysis

Europe is Estimated to Hold 28.6% of the Market Share Owing to the Growing Diabetes Prevalence in this Region

Owing to the growing prevalence of diabetes in Europe, the region is estimated to hold the second-largest share accounting for 28.6% of the global basal insulin (long-acting insulin) market. For instance, according to the World Health Organization, there are approximately 60 million individuals with diabetes in the European Region, or roughly 10.3% of males and 9.6% of females aged 25 years and above. The preponderance of diabetes is rising among all ages in the European Region, principally because of additions in overweight and obesity, harmful diet, and physical laziness.

Competitive Landscape

The major global players in the basal insulin (long-acting insulin) market include: Novo Nordisk AS, Sanofi Aventis, Biocon, Julphar, Pfizer, Ganli Pharmaceutical Co., Ltd, Mylan, Wockhardt, and Eli Lily among others.

Why Purchase the Report?

• To visualize the global basal insulin (long-acting insulin) market segmentation based on product type, application, distribution channels and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of basal insulin (long-acting insulin) market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global basal insulin (long-acting insulin) market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by Distribution Channels
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Market Developments
    • 4.1.1.2. Growing Prevalence
  • 4.1.2. Restraints
    • 4.1.2.1. Side Effect
  • 4.1.3. Opportunity
    • 4.1.3.1. Reimbursement
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's 5 Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID-19
  • 6.1.2. Scenario During COVID-19
  • 6.1.3. Scenario Post COVID-19
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Lantus *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Levemir
• 7.4. Toujeo
• 7.5. Tresiba
• 7.6. Basaglar
• 7.7. Insulin Glargine Biosimilars

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Type 1 Diabetes *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Type 2 Diabetes

9. By Distribution Channels

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 9.1.2. Market Attractiveness Index, By Distribution Channels
• 9.2. Hospital Pharmacies *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Retail Pharmacies
• 9.4. Online Pharmacies

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. The U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. The U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Spain
    • 10.3.6.5. Italy
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan

Australia

• 10.5.6.4. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channels

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Novo Nordisk AS*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Sanofi Aventis
• 12.3. Biocon
• 12.4. Julphar
• 12.5. Pfizer
• 12.6. Ganli Pharmaceutical Co., Ltd
• 12.7. Mylan
• 12.8. Wockhardt
• 12.9. Eli Lily

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us